Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label …
EA Joura, A Ulied, C Vandermeulen, MR Figueroa… - Vaccine, 2021 - Elsevier
Background Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …
Immunogenicity of 2 or 3 doses of 9vHPV vaccine in US female individuals 15 to 26 years of age
AB Berenson, G Panicker, ER Unger, RE Rupp… - NEJM …, 2024 - evidence.nejm.org
Abstract Background Within the United States, a 9-valent human papillomavirus (9vHPV)
vaccine (HPV-6/11/16/18/31/33/45/52/58) is recommended as a two-dose series among …
vaccine (HPV-6/11/16/18/31/33/45/52/58) is recommended as a two-dose series among …
Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: a phase 3 open-label study
H Lv, S Wang, Z Liang, W Yu, C Yan, Y Chen, X Hu… - Vaccine, 2022 - Elsevier
Background The 9-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58)
vaccine was approved for use in Chinese women aged 16–26 years in 2018. This phase 3 …
vaccine was approved for use in Chinese women aged 16–26 years in 2018. This phase 3 …
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
WK Huh, EA Joura, AR Giuliano, OE Iversen… - The Lancet, 2017 - thelancet.com
Background Primary analyses of a study in young women aged 16–26 years showed
efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52 …
efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52 …
[HTML][HTML] Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after …
SE Olsson, JA Restrepo, JC Reina, P Pitisuttithum… - Papillomavirus …, 2020 - Elsevier
Background The nine-valent human papillomavirus (9vHPV) vaccine protects against
infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal …
infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal …
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised …
N Muñoz, R Manalastas, P Pitisuttithum, D Tresukosol… - The Lancet, 2009 - thelancet.com
Background Although the peak incidence of human papillomavirus (HPV) infection occurs in
most populations within 5–10 years of first sexual experience, all women remain at risk for …
most populations within 5–10 years of first sexual experience, all women remain at risk for …
Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
ED Moreira, AR Giuliano, J de Hoon… - Human vaccines & …, 2018 - Taylor & Francis
ABSTRACT A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV
type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from …
type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from …
Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
I Maldonado, M Plata, M Gonzalez… - Human Vaccines & …, 2022 - Taylor & Francis
ABSTRACT Among women aged 27–45 years, the quadrivalent human papillomavirus
(qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic …
(qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic …
[HTML][HTML] Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women
ÁM Ruiz-Sternberg, ED Moreira Jr, JA Restrepo… - Papillomavirus …, 2018 - Elsevier
Background A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV)
vaccine was developed to expand coverage of the previously developed quadrivalent …
vaccine was developed to expand coverage of the previously developed quadrivalent …
The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age
C Zhao, Y Zhao, J Li, M Li, Y Su, X Mi… - Human Vaccines & …, 2022 - Taylor & Francis
The quadrivalent human papillomavirus (4vHPV) vaccine has shown confirmative
effectiveness in preventing HPV-related diseases among women and men around the …
effectiveness in preventing HPV-related diseases among women and men around the …